Advertisement
Screener

Creative Medical Technology Holdings, Inc. (CELZ) Increase (Decrease) in Derivative Liabilities

2.8 / 5 stars · 68/120 Roast Me

Creative Medical Technology Holdings, Inc. Increase (Decrease) in Derivative Liabilities

Creative Medical Technology Holdings, Inc. (CELZ) reported Increase (Decrease) in Derivative Liabilities of $0 for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-12.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDerivativeLiabilities · last filed 2022-08-12

  • Creative Medical Technology Holdings, Inc. increase (decrease) in derivative liabilities for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
  • Creative Medical Technology Holdings, Inc. increase (decrease) in derivative liabilities for the quarter ending 2022-03-31 was $0.00.
  • Creative Medical Technology Holdings, Inc. increase (decrease) in derivative liabilities for the quarter ending 2021-12-31 was $52.06M.
  • Creative Medical Technology Holdings, Inc. increase (decrease) in derivative liabilities for the quarter ending 2021-09-30 was $194.04K.
  • Creative Medical Technology Holdings, Inc. increase (decrease) in derivative liabilities for fiscal 2021 was $26.03M.
  • Creative Medical Technology Holdings, Inc. increase (decrease) in derivative liabilities for fiscal 2020 was -$33.98M.
Period endIncrease (Decrease) in Derivative Liabilities 3 monthIncrease (Decrease) in Derivative Liabilities 6 monthIncrease (Decrease) in Derivative Liabilities 9 monthIncrease (Decrease) in Derivative Liabilities 12 month
2022-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12
$0.00
10-Q · filed 2022-08-12
$52.06M
derived: sum of 3 quarters · filed 2022-08-12
$52.26M
derived: sum of 4 quarters · filed 2022-08-12
2022-03-31$0.00
10-Q · filed 2022-05-13
$52.06M
derived: sum of 2 quarters · filed 2022-05-13
$52.26M
derived: sum of 3 quarters · filed 2022-05-13
$54.51M
derived: sum of 4 quarters · filed 2022-08-12
2021-12-31$52.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30
$52.26M
derived: sum of 2 quarters · filed 2022-03-30
$54.51M
derived: sum of 3 quarters · filed 2022-08-12
$26.03M
10-K · filed 2022-03-30
2021-09-30$194.04K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15
$2.45M
derived: sum of 2 quarters · filed 2022-08-12
-$26.03M
10-Q · filed 2021-11-15
-$56.01M
derived: sum of 4 quarters · filed 2022-08-12
2021-06-30$2.25M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12
-$26.22M
10-Q · filed 2022-08-12
-$56.21M
derived: sum of 3 quarters · filed 2022-08-12
-$57.14M
derived: sum of 4 quarters · filed 2022-08-12
2021-03-31-$28.48M
10-Q · filed 2022-05-13
-$58.46M
derived: sum of 2 quarters · filed 2022-05-13
-$59.39M
derived: sum of 3 quarters · filed 2022-05-13
2020-12-31-$29.98M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30
-$30.91M
derived: sum of 2 quarters · filed 2022-03-30
-$33.98M
10-K · filed 2022-03-30
2020-09-30-$926.53K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15
-$4.00M
10-Q · filed 2021-11-15
2020-06-30-$3.07M
10-Q · filed 2021-08-16

Similar stocks

Stock NameCountryMarket CapPE Ratio
AIM ImmunoTech Inc. (AIM)United States$0.006B
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
WINDTREE THERAPEUTICS INC /DE/ (WINT)United States$0.003B-0.32
VivoSim Labs, INC. (VIVS)United States$0.003B
Calidi Biotherapeutics, Inc. (CLDI)United States$0.003B
CURIS INC (CRIS)United States$0.002B-0.05
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
Silexion Therapeutics Corp (SLXN)$0.001B